PCSK9 and obesity disorder: After adjusting for age, sex, CVD, hypertension, obesity, and diabetes, SH patients who had been seen by cardiology had greater odds of being on any lipid‐lowering medication, high‐intensity statin, or PCSK9 inhibitor compared to those who had not been seen by cardiology (Table 2).